# EDGAR Filing Document

**Accession Number:** 0001790340
**File Stem:** 0000000000-25-009509
**Filing Date:** 2025-9
**Character Count:** 2168
**Document Hash:** 84a894f99611c20c37367c93c2a4189b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009509.hdr.sgml**: 20251125

**ACCESSION NUMBER**: 0000000000-25-009509

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250904

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immuneering Corp
- **CENTRAL INDEX KEY:** 0001790340
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289997

**BUSINESS ADDRESS:**
- **STREET 1:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-500-8080

**MAIL ADDRESS:**
- **STREET 1:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-086561

## Text-Extract

```

                                                           September 4, 2025

Benjamin J. Zeskind
Chief Executive Officer
Immuneering Corporation
245 Main Street, Second Floor
Cambridge, MA 02142

       Re: Immuneering Corporation
           Registration Statement on Form S-3
           Filed September 3, 2025
           File No. 333-289997
Dear Benjamin J. Zeskind:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Joshua Gorsky at 202-551-7836 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Wesley C. Holmes

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._